Manufacturer
AstraZeneca
Contents
Dapagliflozin
Indication
Forxiga is indicated in adults ≥18 years with type 2 diabetes mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on Combination Therapy: Forxiga is indicated in patients with type 2 diabetes mellitus to improve glycemic control: In combination with metformin, when metformin alone with diet and exercise does not provide adequate glycemic control; in combination with a sulfonylurea (SU), when SU alone with diet and exercise does not provide adequate glycemic control; in combination with insulin (alone or with 1 or both of metformin or SU) when the existing therapy, along with diet and exercise, does not provide adequate glycemic control; in combination with a DPP4 inhibitor (with or without metformin) when existing therapy, along with diet and exercise, does not provide adequate glycemic control, in combination with metformin and a sulfonylurea when existing therapy, along with diet and exercise, does not provide adequate glycemic control.
Initial Combination: Forxiga is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when diet and exercise have failed to provide adequate glycemic control and there are poor prospects for response to metformin monotherapy (eg, high initial HbA1c levels).
Instruction
May be taken with or without food
Drug interaction
Increased thiazide & loop diuretic effects; may increase risk of dehydration & hypotension. Pioglitazone
Malaysia
